NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Price Target & More

$95.03 -2.45 (-2.51 %)
(As of 04/23/2018 03:06 PM ET)
Previous Close$97.48
Today's Range$94.77 - $99.30
52-Week Range$49.40 - $153.99
Volume527,954 shs
Average Volume999,549 shs
Market Capitalization$9.76 billion
P/E Ratio-17.84
Dividend YieldN/A
Beta2.68

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Debt-to-Equity Ratio0.02%
Current Ratio12.23%
Quick Ratio12.23%

Price-To-Earnings

Trailing P/E Ratio-17.84
Forward P/E Ratio-13.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$89.91 million
Price / Sales105.87
Cash FlowN/A
Price / CashN/A
Book Value$17.96 per share
Price / Book5.29

Profitability

EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-545.95%
Return on Equity-41.08%
Return on Assets-33.16%

Miscellaneous

Employees749
Outstanding Shares100,170,000

How to Become a New Pot Stock Millionaire

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Zacks' consensus estimate of ($1.38) by $0.10. The biopharmaceutical company earned $37.90 million during the quarter, compared to analysts' expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The company's quarterly revenue was up 116.6% on a year-over-year basis. During the same period last year, the business earned ($1.32) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

21 brokerages have issued 1 year price objectives for Alnylam Pharmaceuticals' stock. Their predictions range from $56.00 to $207.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $139.3333 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results." (4/17/2018)
  • 2. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)
  • 3. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
  • 4. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Michael W. Bonney, Independent Chairman of the Board (Age 58)
  • Barry E. Greene, President (Age 53)
  • John M. Maraganore Ph.D., Chief Executive Officer, Director (Age 54)
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer (Age 39)
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President (Age 54)
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development (Age 54)
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary (Age 62)
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada (Age 57)
  • Peter F. Smith Ph.D., Senior Vice President - Early Development (Age 59)

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

Media headlines about ALNY stock have been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a news impact score of 0.07 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.60 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%) and FMR LLC (15.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $94.86.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $9.76 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  734 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  1,022
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $139.3333, suggesting that the stock has a possible upside of 46.62%. The high price target for ALNY is $207.00 and the low price target for ALNY is $56.00. There are currently 3 sell ratings, 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.622.592.592.48
Ratings Breakdown: 3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $139.3333$131.3810$125.1429$102.90
Price Target Upside: 46.62% upside7.50% downside0.93% upside12.42% downside

Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History

Price Target History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018B. RileyReiterated RatingBuy$200.00MediumView Rating Details
4/2/2018Jefferies GroupReiterated RatingBuyHighView Rating Details
3/28/2018Evercore ISIInitiated CoverageIn -> line$131.18 -> $143.00MediumView Rating Details
3/26/2018JMP SecuritiesBoost Price TargetMkt Outperform -> Outperform$169.00 -> $207.00LowView Rating Details
3/13/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$151.00 -> $154.00HighView Rating Details
2/9/2018NomuraBoost Price TargetSell$86.00LowView Rating Details
2/9/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$165.00 -> $160.00MediumView Rating Details
2/9/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$128.00 -> $118.00MediumView Rating Details
1/25/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$132.00 -> $135.00LowView Rating Details
1/19/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/7/2018Piper JaffrayReiterated RatingBuy$182.00MediumView Rating Details
12/15/2017Goldman SachsUpgradeBuy -> Conviction-BuyHighView Rating Details
11/9/2017CowenReiterated RatingBuy$151.00N/AView Rating Details
11/9/2017JPMorgan ChaseUpgradeNeutral -> OverweightN/AView Rating Details
11/8/2017BarclaysBoost Price TargetOverweight$127.00 -> $158.00N/AView Rating Details
11/3/2017Needham & Company LLCReiterated RatingBuy -> Buy$125.00 -> $152.00N/AView Rating Details
10/30/2017FBR & CoInitiated CoverageBuy -> Buy$150.00N/AView Rating Details
9/21/2017Ladenburg ThalmannReiterated RatingBuy$90.00 -> $146.00LowView Rating Details
9/21/2017Sanford C. BernsteinReiterated RatingOutperform -> Buy$94.00 -> $135.00LowView Rating Details
9/20/2017Stifel NicolausReiterated RatingHold$56.00 -> $83.00LowView Rating Details
9/15/2017InstinetInitiated CoverageReduce -> Reduce$56.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform -> Sell$69.70 -> $67.00LowView Rating Details
3/29/2017UBSInitiated CoverageNeutral -> Neutral$55.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings History and Estimates Chart

Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings Estimates

2018 EPS Consensus Estimate: ($4.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.44)($1.25)($1.35)
Q2 20183($1.64)($1.46)($1.54)
Q3 20183($1.56)($0.69)($1.13)
Q4 20183($1.46)($0.14)($0.93)

Alnylam Pharmaceuticals (NASDAQ ALNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($1.34)N/AView Earnings Details
2/8/2018Q4 2017($1.38)($1.48)$19.31 million$37.90 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.23)($1.34)$28.15 million$17.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.39)($0.23)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.30)($0.35)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.30)($0.29)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.30)($0.19)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.24)($0.22)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.29)($0.55)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.24)($0.19)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.15)($0.23)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.21)($0.07)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.09)($0.31)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.14)($0.03)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.22)$0.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alnylam Pharmaceuticals (NASDAQ:ALNY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.70%
Institutional Ownership Percentage: 92.15%
Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2018Yvonne GreenstreetCOOSell7,221$136.54$985,955.347,221View SEC Filing  
3/20/2018Laurie KeatingSVPSell1,562$149.83$234,034.4616,062View SEC Filing  
3/14/2018Akshay VaishnawInsiderSell88,554$143.10$12,672,077.4055,856View SEC Filing  
3/14/2018Barry E GreenePresidentSell38,460$143.10$5,503,626.0097,544View SEC Filing  
3/13/2018Laurie KeatingSVPSell20,000$145.00$2,900,000.0024,500View SEC Filing  
3/13/2018Paul SchimmelDirectorSell27,823$150.00$4,173,450.0010,000View SEC Filing  
3/9/2018Philip A SharpDirectorSell15,000$129.00$1,935,000.00155,795View SEC Filing  
1/4/2018Michael MasonVPSell36,745$131.59$4,835,274.556,352View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.8017,749View SEC Filing  
12/1/2017Laurie KeatingSVPSell30,000$135.89$4,076,700.0041,500View SEC Filing  
11/22/2017John MaraganoreCEOSell73,415$130.90$9,610,023.50223,125View SEC Filing  
11/15/2017John MaraganoreCEOSell74,000$126.86$9,387,640.00223,710View SEC Filing  
11/2/2017Dennis A AusielloDirectorSell20,000$130.00$2,600,000.0020,000View SEC Filing  
10/30/2017Akshay VaishnawEVPSell33,666$121.46$4,089,072.3645,201View SEC Filing  
10/2/2017Barry E GreenePresidentSell85,316$125.00$10,664,500.00View SEC Filing  
9/20/2017Barry E GreenePresidentSell76,815$100.00$7,681,500.00165,399View SEC Filing  
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.0011,500View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.0021,297View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.005,625View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.0043,047View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00155,795View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00155,795View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.3534,915View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19148,465View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46148,465View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00100View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56133,389View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00140,795View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43133,389View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20133,389View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.003,905View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64106,320View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.003,905View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.6012,588View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.0018,617View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines

Source:
DateHeadline
Alnylam Reports EMA COMP Positive Opinion For ALN-TTRsc02 - Quick FactsAlnylam Reports EMA COMP Positive Opinion For ALN-TTRsc02 - Quick Facts
www.nasdaq.com - April 23 at 8:37 AM
European advisory groups backs Orphan Drug tag for Alnylams ALN-TTRsc02 for ATTR amyloidosisEuropean advisory groups backs Orphan Drug tag for Alnylam's ALN-TTRsc02 for ATTR amyloidosis
seekingalpha.com - April 23 at 8:37 AM
BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated AmyloidosisBRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis
www.reuters.com - April 23 at 8:37 AM
Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated AmyloidosisAlnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
finance.yahoo.com - April 23 at 8:37 AM
Dicerna Pharma (DRNA) Settles Litigation with Alnylam (ALNY)Dicerna Pharma (DRNA) Settles Litigation with Alnylam (ALNY)
www.streetinsider.com - April 21 at 4:57 PM
Alnylam In Deal With Dicerna Resolving Trade Secret Misappropriation, Other SuitAlnylam In Deal With Dicerna Resolving Trade Secret Misappropriation, Other Suit
www.nasdaq.com - April 21 at 8:43 AM
Biotech companies Alnylam, Dicerna settle trade secrets caseBiotech companies Alnylam, Dicerna settle trade secrets case
www.reuters.com - April 20 at 4:58 PM
BRIEF-Alnylam Reaches Settlement Agreement With Dicerna PharmaceuticalsBRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals
www.reuters.com - April 20 at 4:58 PM
Dicerna to pay $27M to settle Alnylam trade secrets lawsuitDicerna to pay $27M to settle Alnylam trade secrets lawsuit
finance.yahoo.com - April 20 at 4:58 PM
Why Dicerna Rocketed Higher TodayWhy Dicerna Rocketed Higher Today
finance.yahoo.com - April 20 at 4:58 PM
Alnylam Pharmaceuticals (ALNY) "Hold" Rating Reiterated at JPMorgan ChaseAlnylam Pharmaceuticals' (ALNY) "Hold" Rating Reiterated at JPMorgan Chase
www.americanbankingnews.com - April 20 at 1:55 PM
Credit Suisse Group Analysts Give Alnylam Pharmaceuticals (ALNY) a $96.00 Price TargetCredit Suisse Group Analysts Give Alnylam Pharmaceuticals (ALNY) a $96.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM
Alnylam Pharmaceuticals (ALNY) Rating Increased to Buy at Zacks Investment ResearchAlnylam Pharmaceuticals (ALNY) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:30 PM
Alnylams President Talks Strategy To Become A Top Biotech Company, Developing An Entirely New Class Of MedicineAlnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
www.benzinga.com - April 18 at 5:17 PM
Your Daily Pharma Scoop: GW Pharmaceuticals Epidiolex, Alnylam Data, Johnson & Johnsons Q1 ResultsYour Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results
seekingalpha.com - April 18 at 8:50 AM
Ladenburg Thalmann Analysts Give Alnylam Pharmaceuticals (ALNY) a $90.00 Price TargetLadenburg Thalmann Analysts Give Alnylam Pharmaceuticals (ALNY) a $90.00 Price Target
www.americanbankingnews.com - April 17 at 11:58 PM
Alnylam Pharma (ALNY) Announces New Positive Clinical Results for GivosiranAlnylam Pharma (ALNY) Announces New Positive Clinical Results for Givosiran
www.streetinsider.com - April 17 at 5:27 PM
Alnylam Pharmaceuticals (ALNY) Upgraded by Zacks Investment Research to HoldAlnylam Pharmaceuticals (ALNY) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 17 at 12:47 PM
Trade secrets battle between Alnylam, Dicerna is just one of manyTrade secrets battle between Alnylam, Dicerna is just one of many
www.msn.com - April 17 at 9:08 AM
Alnylam Pharmaceuticals (ALNY) Disease Background & Givosiran New Clinical Results - SlideshowAlnylam Pharmaceuticals (ALNY) Disease Background & Givosiran New Clinical Results - Slideshow
seekingalpha.com - April 16 at 4:57 PM
Alnylam down 3% on early-stage givosiran data in AHPAlnylam down 3% on early-stage givosiran data in AHP
seekingalpha.com - April 16 at 4:57 PM
Alnylam Pharmaceuticals (ALNY) Now Covered by Analysts at Sanford C. BernsteinAlnylam Pharmaceuticals (ALNY) Now Covered by Analysts at Sanford C. Bernstein
www.americanbankingnews.com - April 15 at 4:30 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by AnalystsAlnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 3:35 PM
Zacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $35.98 MillionZacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $35.98 Million
www.americanbankingnews.com - April 13 at 4:06 AM
Jakafi Continues to Be Strong Growth Driver for Incyte in 2018Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
finance.yahoo.com - April 11 at 5:02 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Earnings of -$1.18 Per ShareAlnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - April 11 at 8:09 AM
Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $50.00Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $50.00
www.americanbankingnews.com - April 10 at 8:24 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $130.00 at Jefferies GroupAlnylam Pharmaceuticals (ALNY) PT Raised to $130.00 at Jefferies Group
www.americanbankingnews.com - April 8 at 8:06 PM
Alnylam Pharmaceuticals (ALNY) Upgraded by Goldman Sachs to BuyAlnylam Pharmaceuticals (ALNY) Upgraded by Goldman Sachs to Buy
www.americanbankingnews.com - April 8 at 3:42 PM
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
finance.yahoo.com - April 6 at 9:01 AM
BidaskClub Lowers Alnylam Pharmaceuticals (ALNY) to SellBidaskClub Lowers Alnylam Pharmaceuticals (ALNY) to Sell
www.americanbankingnews.com - April 5 at 10:26 AM
Alnylam Pharmaceuticals (ALNY) Now Covered by FBR & CoAlnylam Pharmaceuticals (ALNY) Now Covered by FBR & Co
www.americanbankingnews.com - April 4 at 3:32 PM
Alnylam Pharmaceuticals (ALNY) Stock Rating Upgraded by ValuEngineAlnylam Pharmaceuticals (ALNY) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM
With Alnylam Pharma Down More Than 15%, Analyst Says Buy The DipWith Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip
finance.yahoo.com - April 3 at 8:57 AM
Alnylam Pharmaceuticals (ALNY) "Buy" Rating Reaffirmed at B. RileyAlnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - April 2 at 5:18 PM
Alnylam Falls on Pfizers Rare Disease Drug SuccessAlnylam Falls on Pfizer's Rare Disease Drug Success
www.zacks.com - April 2 at 5:02 PM
Alnylam and Ionis continue down movesAlnylam and Ionis continue down moves
seekingalpha.com - April 2 at 5:02 PM
Alnylam Pharmaceuticals (ALNY) "Buy" Rating Reiterated at Jefferies GroupAlnylam Pharmaceuticals' (ALNY) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 2 at 3:16 PM
Alnylam Pharmaceuticals (ALNY) Now Covered by B. RileyAlnylam Pharmaceuticals (ALNY) Now Covered by B. Riley
www.americanbankingnews.com - April 2 at 2:04 PM
Barclays Increases Alnylam Pharmaceuticals (ALNY) Price Target to $158.00Barclays Increases Alnylam Pharmaceuticals (ALNY) Price Target to $158.00
www.americanbankingnews.com - April 1 at 11:23 AM
B. Riley Cuts Alnylam Pharmaceuticals (ALNY) Price Target to $220.00B. Riley Cuts Alnylam Pharmaceuticals (ALNY) Price Target to $220.00
www.americanbankingnews.com - April 1 at 10:34 AM
Alnylam Pharmaceuticals (ALNY) Upgraded at JPMorgan ChaseAlnylam Pharmaceuticals (ALNY) Upgraded at JPMorgan Chase
www.americanbankingnews.com - March 31 at 8:16 PM
Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $130.00Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $130.00
www.americanbankingnews.com - March 31 at 5:28 PM
Alnylam Pharma (ALNY) Announces New Clinical Results from the APOLLO Phase 3 Study of PatisiranAlnylam Pharma (ALNY) Announces New Clinical Results from the APOLLO Phase 3 Study of Patisiran
www.streetinsider.com - March 30 at 8:53 AM
Alnylam and Ionis in the red on positive late-stage data on Pfizers amyloidosis drug tafamidisAlnylam and Ionis in the red on positive late-stage data on Pfizer's amyloidosis drug tafamidis
seekingalpha.com - March 29 at 5:02 PM
Alnylam Pharmaceuticals, Inc. (ALNY) COO Yvonne Greenstreet Sells 7,221 SharesAlnylam Pharmaceuticals, Inc. (ALNY) COO Yvonne Greenstreet Sells 7,221 Shares
www.americanbankingnews.com - March 28 at 10:31 PM
Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral InitiationDicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation
www.msn.com - March 28 at 4:56 PM
Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
finance.yahoo.com - March 28 at 4:56 PM
Alnylam Pharmaceuticals (ALNY) Lowered to Hold at BidaskClubAlnylam Pharmaceuticals (ALNY) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:54 AM
Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on AmyloidosisAlnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
finance.yahoo.com - March 28 at 9:03 AM

SEC Filings

Alnylam Pharmaceuticals (NASDAQ:ALNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alnylam Pharmaceuticals (NASDAQ:ALNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alnylam Pharmaceuticals (NASDAQ ALNY) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.